EGFR tyrosine kinase inhibitors (TKIs) were the first to trigger the molecular profiling of lung cancer, as they demonstrated high response rates in tumors with EGFR exon 19 and 21 drug-sensitizing mutations. This evidence concerns the gene EGFR and lung carcinoma.